Old Web
English
Sign In
Acemap
>
authorDetail
>
James A. Torchia
James A. Torchia
Harvard University
Nivolumab
Ipilimumab
Pathology
Colorectal cancer
Cancer research
4
Papers
22
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Emerging concepts in PD-1 checkpoint biology.
2021
Seminars in Immunology
Kristen E. Pauken
James A. Torchia
Apoorvi Chaudhri
Arlene H. Sharpe
Gordon J. Freeman
Show All
Source
Cite
Save
Citations (5)
Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: Checkpoint Inhibitors for MSI-H/dMMR mCRC
2019
Cancer
Jacqueline N. Chu
Jin Choi
Sassan Ostvar
James A. Torchia
Kerry Lynn Reynolds
Angela C. Tramontano
Justin F. Gainor
Daniel C. Chung
Jeffrey W. Clark
Chin Hur
Show All
Source
Cite
Save
Citations (17)
Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
2018
Journal of Clinical Oncology
Jacqueline N. Chu
Jin G. Choi
Sassan Ostvar
James A. Torchia
Kerry Lynn Reynolds
Justin F. Gainor
Daniel C. Chung
Jeffrey W. Clark
Chin Hur
Show All
Source
Cite
Save
Citations (0)
Nivolumab versus nivolumab with ipilimumab versus trifluridine/tipiracil for metastatic microsatellite instability-high colorectal cancer: A modeling decision analysis.
2018
Journal of Clinical Oncology
Jacqueline N. Chu
Jin G. Choi
Sassan Ostvar
James A. Torchia
Kerry Lynn Reynolds
Justin F. Gainor
Daniel C. Chung
Jeffrey W. Clark
Chin Hur
Show All
Source
Cite
Save
Citations (0)
1